On the stock market since 2020, it operates in the world of health and science. It has 19 employees. Now — the numbers.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 70% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 54 buys and 21 sells. Management buying with its own money is usually read as a good sign.
Nothing in the current numbers stands out as a clear risk. Still, no stock is ever risk-free.
On our five-subject report card, RCOR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: RCOR is a high-risk stock — not yet profitable, and its future rides on its product catching on.